ArticleClinicoEconomics and outcomes research : CEOR2021

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis.

Marco Bellone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.